Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immuno-oncology drugs market is estimated to be valued at US$ 17,394.2 in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Immuno-oncology Drugs Market:
Adoption of inorganic growth strategies such as acquisition by key market players is expected to drive the global Immuno-oncology drugs market over the forecast period. For instance, in January 2020, Sanofi, a biopharmaceutical company, announced that they had acquired Synthorx, Inc., a biotech company, this acquisition will allow Sanofi to expand the research and development strategies of oncology and immunology.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271
Immuno-oncology Drugs Market Report Coverage
Report Coverage | Details | |||
Base Year: | 2021 | Market Size in 2022: | US$ 17,394.2 Mn | |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 | |
Forecast Period 2022 to 2030 CAGR: | 16.8% | 2030 Value Projection: | US$ 60,186.2 Mn | |
Geographies covered: |
| |||
Segments covered: |
| |||
Companies covered: | AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE | |||
Growth Drivers: |
| |||
Restraints & Challenges: |
|
Key Market Takeaways:
The global Immuno-oncology drugs market is expected to exhibit a CAGR of 16.8% during the forecast period due to the increasing inorganic strategies such as collaboration and license agreement by the key market players. For instance, in November 2021, Regeneron Pharmaceuticals Inc., a biotechnology company, announced that they had made a research collaboration and license agreement with CytomX Therapeutics, Inc., a biopharmaceutical company, for the conditionally-activated investigational bispecific cancer treatment.
Among disease type, Melanoma is expected to boost the market due to increasing prevalence over the forecast period. For instance, according to the data published by American Cancer Society in January 2022, it was estimated that about 99,780 new melanomas are diagnosed in U.S. (about 57,180 in men and 42,600 in women). The rates of melanoma have been rising rapidly but this has varied by age
Competitive Landscape:
Key players operating in the global immuno-oncology drugs market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1271
Market Segmentation:
- Global Immuno-oncology Drugs Market, By Treatment Type:
- Immune Checkpoint Inhibitors
- PD-1
- PD-L1
- CTLA-4
- Immune System Modulators
- Cancer Vaccines
- Oncolytic Virus
- Others
- Immune Checkpoint Inhibitors
- Global Immuno-oncology Drugs Market, By Disease Type:
- Melanoma
- Lung Cancer
- Blood Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Bladder Cancer
- Others (Breast Cancer, Thyroid Cancer, etc.)
- Global Immuno-oncology Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Immuno-oncology Drugs Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- By Country
- North America
Related Market Intelligence Reports:
Digestive Drugs Market, By Type (Branded and Generic), By Drug Class (5-aminosalicylates, GI stimulants, Laxatives, Antacids, H2 Antagonists, Antidiarrheals, Others), By Route of Administration (Oral, Intravenous, Others), By Application (Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome, Ulcerative Colitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
DNA Sequencing Market, by Product Type (Consumables, Instruments, and Services), by Technology (Sanger Sequencing, Next-Generation Sequencing, Third- Generation DNA Sequencing, and Others), by Application (Oncology, Reproductive Health, Clinical Investigation, Agrigenomics & Forensics, Metagenomics, Epidemiology & Drug Development, and Others), by End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Clinical Research, and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
![](https://ml.globenewswire.com/media/MWM5MjkyNDgtNTdhMC00ZmUzLWIxZjMtNTQ2ODdkNjdmMTA3LTExMDI1OTQ=/tiny/Coherent-Market-Insights.png)